Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADVM NASDAQ:LPCN NASDAQ:NVCT NASDAQ:ORMP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADVMAdverum Biotechnologies$4.07-2.6%$3.84$1.78▼$8.21$87.71M0.98270,795 shs13.57 million shsLPCNLipocine$2.90+3.9%$2.97$2.65▼$6.17$15.12M1.2958,099 shs36,503 shsNVCTNuvectis Pharma$6.20+3.2%$6.25$4.44▼$11.80$153M-0.2976,508 shs197,270 shsORMPOramed Pharmaceuticals$2.39+0.8%$2.32$1.82▼$3.09$98M1.62129,858 shs136,448 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADVMAdverum Biotechnologies-2.63%-5.13%-6.22%+50.74%-49.88%LPCNLipocine+3.94%-3.97%+5.07%-15.70%-46.98%NVCTNuvectis Pharma+3.16%+0.49%+4.20%-20.31%-27.06%ORMPOramed Pharmaceuticals+0.84%+7.17%-0.42%+10.65%+0.42%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADVMAdverum Biotechnologies$4.07-2.6%$3.84$1.78▼$8.21$87.71M0.98270,795 shs13.57 million shsLPCNLipocine$2.90+3.9%$2.97$2.65▼$6.17$15.12M1.2958,099 shs36,503 shsNVCTNuvectis Pharma$6.20+3.2%$6.25$4.44▼$11.80$153M-0.2976,508 shs197,270 shsORMPOramed Pharmaceuticals$2.39+0.8%$2.32$1.82▼$3.09$98M1.62129,858 shs136,448 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADVMAdverum Biotechnologies-2.63%-5.13%-6.22%+50.74%-49.88%LPCNLipocine+3.94%-3.97%+5.07%-15.70%-46.98%NVCTNuvectis Pharma+3.16%+0.49%+4.20%-20.31%-27.06%ORMPOramed Pharmaceuticals+0.84%+7.17%-0.42%+10.65%+0.42%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADVMAdverum Biotechnologies 2.40Hold$16.80312.78% UpsideLPCNLipocine 2.67Moderate Buy$8.00175.86% UpsideNVCTNuvectis Pharma 2.50Moderate Buy$15.33147.31% UpsideORMPOramed Pharmaceuticals 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest LPCN, ADVM, NVCT, and ORMP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/25/2025NVCTNuvectis PharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/25/2025ORMPOramed PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)10/24/2025ADVMAdverum BiotechnologiesTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$5.0010/24/2025ADVMAdverum BiotechnologiesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/9/2025ADVMAdverum BiotechnologiesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold10/8/2025ADVMAdverum BiotechnologiesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025LPCNLipocineWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025NVCTNuvectis PharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025ORMPOramed PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)9/27/2025ADVMAdverum BiotechnologiesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell ➝ Sell (D-)9/27/2025LPCNLipocineWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 10/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADVMAdverum Biotechnologies$1M85.39N/AN/A$3.40 per share1.20LPCNLipocine$11.20M1.40N/AN/A$3.93 per share0.74NVCTNuvectis PharmaN/AN/AN/AN/A$0.50 per shareN/AORMPOramed Pharmaceuticals$2M49.00N/AN/A$3.61 per share0.66Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADVMAdverum Biotechnologies-$130.93M-$7.85N/AN/AN/AN/A-297.29%-101.40%11/3/2025 (Estimated)LPCNLipocine$10K-$0.87N/A∞N/AN/A-23.59%-21.91%11/6/2025 (Estimated)NVCTNuvectis Pharma-$19M-$1.17N/AN/AN/AN/A-150.81%-94.84%11/4/2025 (Estimated)ORMPOramed Pharmaceuticals-$19.06M-$0.35N/AN/AN/AN/A-19.37%-18.28%11/6/2025 (Estimated)Latest LPCN, ADVM, NVCT, and ORMP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025LPCNLipocine-$0.56N/AN/AN/AN/AN/A11/6/2025N/AORMPOramed Pharmaceuticals-$0.04N/AN/AN/AN/AN/A11/4/2025Q3 2025NVCTNuvectis Pharma-$0.24N/AN/AN/AN/AN/A11/3/2025Q3 2025ADVMAdverum Biotechnologies-$1.80N/AN/AN/AN/AN/A8/14/2025Q2 2025ORMPOramed Pharmaceuticals-$0.04-$0.05-$0.01$0.31N/AN/A8/12/2025Q2 2025ADVMAdverum Biotechnologies-$2.24-$2.34-$0.10-$2.34N/AN/A8/5/2025Q2 2025LPCNLipocine-$0.41-$0.41N/A-$0.41$1.00 million$0.62 million8/5/2025Q2 2025NVCTNuvectis Pharma-$0.25-$0.30-$0.05-$0.30N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADVMAdverum BiotechnologiesN/AN/AN/AN/AN/ALPCNLipocineN/AN/AN/AN/AN/ANVCTNuvectis PharmaN/AN/AN/AN/AN/AORMPOramed PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADVMAdverum BiotechnologiesN/A1.541.54LPCNLipocineN/A12.7112.71NVCTNuvectis PharmaN/A2.662.66ORMPOramed PharmaceuticalsN/A26.8226.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADVMAdverum Biotechnologies48.17%LPCNLipocine9.11%NVCTNuvectis Pharma96.77%ORMPOramed Pharmaceuticals12.73%Insider OwnershipCompanyInsider OwnershipADVMAdverum Biotechnologies6.00%LPCNLipocine6.35%NVCTNuvectis Pharma30.52%ORMPOramed Pharmaceuticals17.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADVMAdverum Biotechnologies19020.98 million19.73 millionOptionableLPCNLipocine105.42 million5.08 millionNo DataNVCTNuvectis Pharma825.46 million17.69 millionNot OptionableORMPOramed Pharmaceuticals1041.00 million33.71 millionOptionableLPCN, ADVM, NVCT, and ORMP HeadlinesRecent News About These CompaniesOramed Pharm Repurchases Shares, Ends Joint VentureOctober 24 at 12:40 PM | msn.comOramed Releases Letter to Shareholders, Highlighting Developments in its Oral Insulin Program, Significant Investment Appreciation, and Upcoming Growth InitiativesOctober 23 at 8:55 AM | prnewswire.comOramed Pharmaceuticals (NASDAQ:ORMP) Stock Price Passes Above Fifty Day Moving Average - Time to Sell?October 21, 2025 | marketbeat.comWeiss Ratings Reaffirms Sell (D) Rating for Oramed Pharmaceuticals (NASDAQ:ORMP)October 10, 2025 | marketbeat.comOramed Pharm Completes Warrant Repurchase AgreementOctober 6, 2025 | tipranks.comOramed Pharmaceuticals Inc. (NASDAQ:ORMP) Short Interest Down 35.7% in SeptemberOctober 5, 2025 | marketbeat.comOramed Pharm Approves Stock Incentive Plan AmendmentAugust 21, 2025 | tipranks.comWith Substantial Liquidity, ORMP Has Generated Gains & Income From Investment PortfolioJuly 29, 2025 | msn.comORMP - Oramed Pharmaceuticals Inc Trailing Returns - MorningstarJuly 2, 2025 | morningstar.comMOramed Pharmaceuticals Inc. (ORMP) - Yahoo FinanceJuly 2, 2025 | ca.finance.yahoo.comORMP - Oramed Pharmaceuticals Inc Executives - MorningstarJune 27, 2025 | morningstar.comMWe're Not Very Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn RateJune 27, 2025 | finance.yahoo.comOramed Pharm Extends Stock Buyback ProgramMay 21, 2025 | tipranks.comThe past three years for Oramed Pharmaceuticals (NASDAQ:ORMP) investors has not been profitableMay 17, 2025 | finance.yahoo.comOramed Pharmaceuticals Inc.: Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau MedicalApril 28, 2025 | finanznachrichten.deAlpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed PharmaceuticalsApril 28, 2025 | globenewswire.comOramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau MedicalApril 28, 2025 | prnewswire.comORMP: Upcoming Expected Milestones Include OraTech Spin-Off & IPO, Launch of Phase 3 TrialApril 3, 2025 | finance.yahoo.comOramed Pharmaceuticals And 2 Other Penny Stocks With Promising PotentialMarch 15, 2025 | finance.yahoo.comOramed Pharmaceuticals Issues Letter to ShareholdersMarch 4, 2025 | prnewswire.comOraMed Enters Global Licensing Deal for Lidocaine ProductMarch 1, 2025 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLPCN, ADVM, NVCT, and ORMP Company DescriptionsAdverum Biotechnologies NASDAQ:ADVM$4.07 -0.11 (-2.63%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$4.08 +0.01 (+0.34%) As of 10/24/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.Lipocine NASDAQ:LPCN$2.90 +0.11 (+3.94%) Closing price 10/24/2025 03:59 PM EasternExtended Trading$2.88 -0.02 (-0.69%) As of 10/24/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.Nuvectis Pharma NASDAQ:NVCT$6.20 +0.19 (+3.16%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$6.20 0.00 (0.00%) As of 10/24/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.Oramed Pharmaceuticals NASDAQ:ORMP$2.39 +0.02 (+0.84%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$2.32 -0.07 (-2.93%) As of 10/24/2025 04:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 10/20 - 10/24 Freeport-McMoRan Posts Strong Earnings Despite Indonesia Shutdown Tractor Supply Stock Looks Like a Buy-and-Hold Winner Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Fal.Con Europe Could Be CrowdStrike’s Early Earnings Catalyst Logitech Eyes Breakout Before Earnings—Citigroup Sees 30% Upside Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
